Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Matching Perfusion and Metabolic Activity in HFpEF
NCT04913805Phase 2Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Oct 2021
- Primary completion
- May 2027
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial of potassium nitrate, propionyl-L-carnitine and nicotinamide riboside in heart failure with preserved ejection fraction (HFpEF) (3 arms), sponsored by University of Pennsylvania. Primary endpoint: Submaximal Exercise Endurance at 6 weeks. Started Oct 2021; status: recruiting.
02
Drugs
potassium nitratepropionyl-L-carnitinenicotinamide riboside
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04913805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04913805.